Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/16/2024 | $56.00 → $38.00 | Buy | BTIG Research |
| 2/28/2024 | $37.00 → $24.00 | Overweight → Neutral | Piper Sandler |
| 5/19/2023 | $42.00 | Buy | BofA Securities |
| 12/6/2022 | Outperform | Cowen | |
| 10/13/2022 | $58.00 | Outperform → Strong Buy | Raymond James |
| 9/21/2022 | $37.00 | Overweight | JP Morgan |
| 7/6/2022 | $50.00 | Buy | Canaccord Genuity |
| 2/24/2022 | $61.00 → $55.00 | Buy | HC Wainwright & Co. |
4 - Xencor Inc (0001326732) (Issuer)
4 - Xencor Inc (0001326732) (Issuer)
4 - Xencor Inc (0001326732) (Issuer)
4 - Xencor Inc (0001326732) (Issuer)
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the third quarter ended September 30, 2024 and provided a review of recent business and clinical-stage program updates. "In September, we provided updates across our clinical pipeline of XmAb® bispecific T-cell engagers in oncology and introduced our new autoimmune programs, including the B-cell depleting bispecific antibodies plamotamab and XmAb657, and XmAb942, our high potency anti-TL1A antibody with extended half-life in development for patients with inflammatory bowel disease. This week, we
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has initiated dosing of healthy volunteers in the first-in-human study of XmAb®942, an investigational high-potency extended half-life anti-TL1A antibody. Xencor continues to expect initial data from the ongoing study during the first half of 2025. "An anti-TL1A antibody engineered for improved target coverage with long duration of action could transform the clinician's therapeutic toolbox in inflammatory bowel disease," said Kenneth Hung, M.D., Ph.D., senior vice president, clinical development at Xencor. "W
-- XmAb942 on track for first subject dosing in Phase 1 healthy volunteer study in Q4 2024 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that preclinical data on XmAb942 were published in a poster to be presented during United European Gastroenterology (UEG) Week on Tuesday, October 15 in Vienna, Austria. XmAb942 is a high-potency, extended half-life, investigational anti-TL1A antibody to be developed for patients with inflammatory bowel diseases, such as ulcerative colitis (UC) and Crohn's disease (CD). The first generation of anti-TL1A antibodies, designed
BTIG Research reiterated coverage of Xencor with a rating of Buy and set a new price target of $38.00 from $56.00 previously
Piper Sandler downgraded Xencor from Overweight to Neutral and set a new price target of $24.00 from $37.00 previously
BofA Securities initiated coverage of Xencor with a rating of Buy and set a new price target of $42.00
10-Q - Xencor Inc (0001326732) (Filer)
8-K - Xencor Inc (0001326732) (Filer)
8-K - Xencor Inc (0001326732) (Filer)
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at Seagen Inc., where he was instrumental in the company's transformation into a global, multi-product organization that generated over $2 billion in annual revenue. "Bart's exceptional track record in financial planning and analysis
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Barbara J. Klencke, M.D., to its board of directors. Dr. Klencke has more than 20 years of biopharmaceutical product development experience, and she most recently served as chief medical officer and chief development officer at Sierra Oncology through mid-2023. While at Sierra Oncology, she built a highly effective clinical development organization and led its strategy and execution, culminating in the approval of Ojjaara™ for myelofibrosis following the company's acquisition by GSK. "D
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer. Dr. Valente has more than 20 years of experience in late-stage biopharmaceutical product development, and she most recently served as a senior vice president at Genentech, a member of the Roche Group, and as its global head and co-lead of global product development of its oncology and hematology therapeutic area. Dr. Valente has served as an independent member of Xencor's Board of Directors since September 2022
In the latest quarter, 5 analysts provided ratings for Xencor (NASDAQ:XNCR), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 1 2 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $35.4, a high estimate of $40.00, and a low estimate of $31.00. A decline of 17.29% from the prior average price target is evident in the current aver
Raymond James analyst Sean McCutcheon maintains Xencor (NASDAQ:XNCR) with a Strong Buy and lowers the price target from $58 to $40.
BMO Capital analyst Etzer Darout maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $34 to $32.
– Phase 1 healthy volunteer study of half-life extended anti-TL1A antibody XmAb942 to dose first subject in Q4 2024, with data anticipated in the first half of 2025 – – XmAb® T-cell engagers plamotamab (CD20 x CD3) and XmAb657 (CD19 x CD3) to be evaluated in autoimmune diseases, with respective Phase 1b/2a and Phase 1 studies to initiate in 2025 – – Ongoing Phase 1 dose escalation of XmAb819 (ENPP3 x CD3) in advanced clear cell renal cell carcinoma shows initial encouraging clinical activity including RECIST responses – – Management hosting webcast and conference call at 8:00 a.m. ET / 5:00 a.m. PT today – Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that management will host a webcast and conference call at 8:00 a.m. ET (5:00 a.m. PT) on Monday, September 9, 2024 to introduce new XmAb® programs in development for the treatment of patients with autoimmune diseases and to provide updates on continued progress in dose escalation with first-in-class oncology programs, including XmAb819 (ENPP3 x CD3) in patients with advanced clear cell renal cell carcinoma and XmAb808 (B7-H3 x CD28) in patients with advanced solid tumors. The live webcast may be accessed through "E
-- Clinical development focus on high-potential XmAb® T cell engagers and selective dual checkpoint inhibitor, vudalimab -- -- Vudalimab (PD-1 x CTLA-4) monotherapy generally well tolerated with encouraging clinical benefit for patients with high-risk mCRPC who have advanced beyond standard of care therapy -- -- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a review of recent business and clinical highlights.
SC 13G/A - Xencor Inc (0001326732) (Subject)
SC 13G/A - Xencor Inc (0001326732) (Subject)
SC 13G/A - Xencor Inc (0001326732) (Subject)